Study of Dara-Pembro for Multiple Myeloma Patients

Summary

This is a phase II, single-arm, open-label study in subjects with relapsed and/or refractory multiple myeloma (RRMM) comparing Pembrolizumab (Pembro) in combination with Daratumumab (Dara) to the historical control of Daratumumab.

Timeline

Start

2021-06-09

Primary completion

2027-05

Completion

2027-05

Outcome

Outcome not reported

Stopped (Enrollment): “Low enrollment due to competing studies”

Drugs

Indications